Logo

Karyopharm Signs an Exclusive License Agreement with Menarini to Commercialize Nexpovio (selinexor) for Oncology

Share this

Karyopharm Signs an Exclusive License Agreement with Menarini to Commercialize Nexpovio (selinexor) for Oncology

Shots:

  • Karyopharm to receive $75M up front & is eligible to receive ~$202.5M upon achievement of development & sales-based milestones along with royalties on net sales of Nexpovio
  • Menarini gets a non-exclusive/exclusive license to develop & commercialize selinexor for Hematologic & oncology indications in the EU, UK, and other countries & also get non-exclusive license to package and label the product in/outside of the Territory for oncology indications
  • Nexpovio is an oral SINE compound & is marketed as Xpovio in the US. Additionally, the EMA has validated the MAA for Nexpovio + Velcade & low-dose dexamethasone to treat MM while CHMP will review the MAA & is expected to be completed in H1’22

Ref: Karyopharm | Image: Karyopharm 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions